Actively Recruiting
Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
Led by The Skin Center Dermatology Group · Updated on 2026-02-10
10
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.
CONDITIONS
Official Title
Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Clinical and/or histopathologic diagnosis of lichen planopilaris
- Presence of scalp pruritus
- Average Peak Pruritus Numerical Rating Scale (PP-NRS) score of 4 or higher in the 7 days before Day 1
- Ability and willingness to provide written informed consent and comply with study procedures
- Willingness to undergo optional scalp biopsy for research purposes
You will not qualify if you...
- Other forms of alopecia that may interfere with study assessments
- Any systemic disease associated with hair loss
- Inflammatory or infectious scalp disease that may interfere with the study
- Any other conditions associated with pruritus
- Prior use of nemolizumab
- Current treatment with systemic or topical JAK inhibitors or biologics without at least a 12-week washout period
- Current treatment with DMARDs without at least a 12-week washout period
- Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or biologics
- Current treatment with topical or intralesional corticosteroids without at least a 4-week washout period
- Current use of other hair loss treatments unless stable for 6 months or completed a 3-month washout
- Allergy or hypersensitivity to nemolizumab or any excipients
- Pregnancy or unwillingness to use highly effective contraception
- Any medical condition that may interfere with participation or interpretation of results in the investigator's opinion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Skin Center Dermatology Group
New City, New York, United States, 10956
Actively Recruiting
Research Team
P
Peter Friedman, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here